Reata Pharmaceuticals Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (31)

View All

Latest Posts

About This Stock More About This Stock
Reata Pharmaceuticals, Inc. (RETA): These Hedge Funds Sold Prior To Large Gains
Article By: Insider Monkey
Wednesday, October 30, 2019 10:18 AM EDT
Judging by the fact that Reata Pharmaceuticals, Inc. has faced falling interest from the aggregate hedge fund industry, it’s easy to see that there lies a certain “tier” of fund managers that slashed their positions entirely heading into Q3.
In this article: RETA
Read
10 Stock Tips From The Street’s Best Analysts
Article By: TipRanks
Sunday, July 29, 2018 4:39 PM EDT
Using the updated stock screener from the generated results, these 10 stocks stood out. Bear in mind the analyst consensus is based on ratings from the last three months.
In this article: EW, MA, MPC, MPWR, AMZN, MU, EXAS, GOOGL, WIX, RETA
Read
Five Biotech IPOs Lead The Way In 2016
Article By: Don Dion
Friday, November 25, 2016 10:33 AM EDT
While the IPO market was relatively weak in 2016 overall, biopharma IPOs excelled. We have been particularly impressed with AveXis, Clearside Biomedical, Protagonist Therapeutics, Reata Pharma, and bluebird bio.
In this article: BLUE, AVXS, RETA, PTGX, CLSD
Read
We're Cautious On The Reata Pharmaceuticals IPO
Article By: Don Dion
Wednesday, May 25, 2016 9:26 AM EDT
Reata Pharmaceuticals will offer 4.0 million shares at an expected price range of $14 to $16. RETA filed for the IPO on January 4, 2016. We suggest investors consider caution.
In this article: RETA
Read
All Posts

Latest Tweets for $RETA

No tweets yet!

PARTNER HEADLINES